Literature DB >> 22441543

Estimating rates of carriage acquisition and clearance and competitive ability for pneumococcal serotypes in Kenya with a Markov transition model.

Marc Lipsitch1, Osman Abdullahi, Alexander DʼAmour, Wen Xie, Daniel M Weinberger, Eric Tchetgen Tchetgen, J Anthony G Scott.   

Abstract

BACKGROUND: There are more than 90 serotypes of Streptococcus pneumoniae, with varying biologic and epidemiologic properties. Animal studies suggest that carriage induces an acquired immune response that reduces duration of colonization in a nonserotype-specific fashion.
METHODS: We studied pneumococcal nasopharyngeal carriage longitudinally in Kenyan children 3-59 months of age, following up positive swabs at days 2, 4, 8, 16, and 32 and then monthly thereafter until 2 swabs were negative for the original serotype. As previously reported, 1868/2840 (66%) of children swabbed at baseline were positive. We estimated acquisition, clearance, and competition parameters for 27 serotypes using a Markov transition model.
RESULTS: Point estimates of type-specific acquisition rates ranged from 0.00025/d (type 1) to 0.0031/d (type 19F). Point estimates of time to clearance (inverse of type-specific immune clearance rate) ranged from 28 days (type 20) to 124 days (type 6A). For the serotype most resistant to competition (type 19F), acquisition of other serotypes was 52% less likely (95% confidence interval = 37%-63%) than in an uncolonized host. Fitness components (carriage duration, acquisition rate, lack of susceptibility to competition) were positively correlated with each other and with baseline prevalence, and were associated with biologic properties previously shown to associate with serotype. Duration of carriage declined with age for most serotypes.
CONCLUSIONS: Common S. pneumoniae serotypes appear superior in many dimensions of fitness. Differences in rate of immune clearance are attenuated as children age and become capable of more rapid clearance of the longest-lived serotypes. These findings provide information for comparison after introduction of pneumococcal conjugate vaccine.

Entities:  

Mesh:

Year:  2012        PMID: 22441543      PMCID: PMC3670084          DOI: 10.1097/EDE.0b013e31824f2f32

Source DB:  PubMed          Journal:  Epidemiology        ISSN: 1044-3983            Impact factor:   4.822


  46 in total

1.  Geographic diversity and temporal trends of antimicrobial resistance in Streptococcus pneumoniae in the United States.

Authors:  Althea W McCormick; Cynthia G Whitney; Monica M Farley; Ruth Lynfield; Lee H Harrison; Nancy M Bennett; William Schaffner; Arthur Reingold; James Hadler; Paul Cieslak; Matthew H Samore; Marc Lipsitch
Journal:  Nat Med       Date:  2003-03-10       Impact factor: 53.440

2.  Aetiology, outcome, and risk factors for mortality among adults with acute pneumonia in Kenya.

Authors:  J A Scott; A J Hall; C Muyodi; B Lowe; M Ross; B Chohan; K Mandaliya; E Getambu; F Gleeson; F Drobniewski; K Marsh
Journal:  Lancet       Date:  2000-04-08       Impact factor: 79.321

3.  Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group.

Authors:  S Black; H Shinefield; B Fireman; E Lewis; P Ray; J R Hansen; L Elvin; K M Ensor; J Hackell; G Siber; F Malinoski; D Madore; I Chang; R Kohberger; W Watson; R Austrian; K Edwards
Journal:  Pediatr Infect Dis J       Date:  2000-03       Impact factor: 2.129

4.  Competition among Streptococcus pneumoniae for intranasal colonization in a mouse model.

Authors:  M Lipsitch; J K Dykes; S E Johnson; E W Ades; J King; D E Briles; G M Carlone
Journal:  Vaccine       Date:  2000-06-15       Impact factor: 3.641

5.  Intrinsic epidemicity of Streptococcus pneumoniae depends on strain serotype and antibiotic susceptibility pattern.

Authors:  Matthieu Domenech de Cellès; Lulla Opatowski; Jérôme Salomon; Emmanuelle Varon; Claude Carbon; Pierre-Yves Boëlle; Didier Guillemot
Journal:  Antimicrob Agents Chemother       Date:  2011-07-25       Impact factor: 5.191

6.  Ability of pneumococcal serotypes and clones to cause acute otitis media: implications for the prevention of otitis media by conjugate vaccines.

Authors:  William P Hanage; Kari Auranen; Ritva Syrjänen; Elja Herva; P Helena Mäkelä; Terhi Kilpi; Brian G Spratt
Journal:  Infect Immun       Date:  2004-01       Impact factor: 3.441

7.  Genetic basis for the structural difference between Streptococcus pneumoniae serotype 15B and 15C capsular polysaccharides.

Authors:  Saskia van Selm; Lisette M van Cann; Marc A B Kolkman; Bernard A M van der Zeijst; Jos P M van Putten
Journal:  Infect Immun       Date:  2003-11       Impact factor: 3.441

8.  Stability of serotypes during nasopharyngeal carriage of Streptococcus pneumoniae.

Authors:  Emma Meats; Angela B Brueggemann; Mark C Enright; Karen Sleeman; David T Griffiths; Derrick W Crook; Brian G Spratt
Journal:  J Clin Microbiol       Date:  2003-01       Impact factor: 5.948

Review 9.  Streptococcus pneumoniae colonisation: the key to pneumococcal disease.

Authors:  D Bogaert; R De Groot; P W M Hermans
Journal:  Lancet Infect Dis       Date:  2004-03       Impact factor: 25.071

10.  Pneumococcal carriage in United Kingdom families: estimating serotype-specific transmission parameters from longitudinal data.

Authors:  Alessia Melegaro; Yoon Choi; Richard Pebody; Nigel Gay
Journal:  Am J Epidemiol       Date:  2007-05-21       Impact factor: 4.897

View more
  44 in total

Review 1.  Host-Pathogen Interactions in Gram-Positive Bacterial Pneumonia.

Authors:  Jennifer A Grousd; Helen E Rich; John F Alcorn
Journal:  Clin Microbiol Rev       Date:  2019-05-29       Impact factor: 26.132

2.  Evolution of antibiotic resistance is linked to any genetic mechanism affecting bacterial duration of carriage.

Authors:  Sonja Lehtinen; François Blanquart; Nicholas J Croucher; Paul Turner; Marc Lipsitch; Christophe Fraser
Journal:  Proc Natl Acad Sci U S A       Date:  2017-01-17       Impact factor: 11.205

3.  Vaccination can drive an increase in frequencies of antibiotic resistance among nonvaccine serotypes of Streptococcus pneumoniae.

Authors:  Uri Obolski; José Lourenço; Craig Thompson; Robin Thompson; Andrea Gori; Sunetra Gupta
Journal:  Proc Natl Acad Sci U S A       Date:  2018-03-06       Impact factor: 11.205

4.  Pathogen diversity and hidden regimes of apparent competition.

Authors:  Sarah Cobey; Marc Lipsitch
Journal:  Am Nat       Date:  2012-11-27       Impact factor: 3.926

5.  Linking data and models: the importance of statistical analyses to inform models for the transmission dynamics of infections.

Authors:  Virginia E Pitzer; Nicole E Basta
Journal:  Epidemiology       Date:  2012-07       Impact factor: 4.822

6.  Estimating strain-specific and overall efficacy of polyvalent vaccines against recurrent pathogens from a cross-sectional study.

Authors:  Kari Auranen; Hanna Rinta-Kokko; M Elizabeth Halloran
Journal:  Biometrics       Date:  2013-02-04       Impact factor: 2.571

7.  Potential impact of introducing the pneumococcal conjugate vaccine into national immunisation programmes: an economic-epidemiological analysis using data from India.

Authors:  Itamar Megiddo; Eili Klein; Ramanan Laxminarayan
Journal:  BMJ Glob Health       Date:  2018-05-09

8.  Surface charge of Streptococcus pneumoniae predicts serotype distribution.

Authors:  Yuan Li; Daniel M Weinberger; Claudette M Thompson; Krzysztof Trzciński; Marc Lipsitch
Journal:  Infect Immun       Date:  2013-09-30       Impact factor: 3.441

9.  Impaired innate mucosal immunity in aged mice permits prolonged Streptococcus pneumoniae colonization.

Authors:  Cassandra L Krone; Krzysztof Trzciński; Tomasz Zborowski; Elisabeth A M Sanders; Debby Bogaert
Journal:  Infect Immun       Date:  2013-09-30       Impact factor: 3.441

10.  Novel Strategy To Protect against Influenza Virus-Induced Pneumococcal Disease without Interfering with Commensal Colonization.

Authors:  Christopher J Greene; Laura R Marks; John C Hu; Ryan Reddinger; Lorrie Mandell; Hazeline Roche-Hakansson; Natalie D King-Lyons; Terry D Connell; Anders P Hakansson
Journal:  Infect Immun       Date:  2016-05-24       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.